Estimation of the Number of People With Opioid Addiction in Germany
; ; ; ; ; ;
Background: Opioid addiction is one of the most common substance-related disorders worldwide, and morbidity and mortality due to opioid addiction place a heavy burden on society. Knowing the size of the population that is addicted to opioids is a prerequisite for the development and implementation of appropriate health-policy measures.
Methods: Our estimate for Germany for 2016 is based on an enumeration of opioid-addicted persons who were entered in a registry of persons receiving substitution therapy, an enumeration of persons receiving outpatient and inpatient care for addiction without substitution therapy, an extrapolation to all addiction care facilities, and an estimation of the number of opioid-addicted persons who were not accounted for either in the substitution registry or in addiction care.
Results: The overall estimate of the number of opioid-addicted persons in Germany in 2016 was 166 294 persons (lower and upper bounds: 164 794 and 167 794), including 123 988 men (122 968 to 125 007) and 42 307 women (41 826 to 42 787). The estimates for each German federal state per 1000 inhabitants ranged from 0.1 in Brandenburg to 3.0 in North Rhine-Westphalia and 5.5 in Bremen. The average value across Germany was 3.1 per 1000 inhabitants.
Conclusion: Comparisons with earlier estimates suggest that the number of persons addicted to opioids in Germany has hardly changed over the past 20 years. Despite methodological limitations, this estimate can be considered highly valid. Nearly all persons who are addicted to opioids are in contact with the addiction care system.
Opioid addiction is one of the most common substance-related disorders worldwide. It is responsible for the majority of the morbidity and mortality caused by drugs in the population (1). Opioids include both synthetic (e.g. heroin, methadone, buprenorphine, fentanyl) and plant-derived substances (opiates, e.g. codeine and morphine). Opioids carry major risks of physical and pharmacological dependency (2). Intravenous use, in particular, is associated with a non-negligible risk of communicable diseases (3) or death due to overdose or the long-term consequences of use (4). Finally, there is an increased risk of criminal behavior, specifically drug-related crime (5).
Knowing how many individuals are addicted to opioids is important for setting health policy (6). In the first instance, calculations in Germany concern addiction caused by taking illegal opioid-containing substances. A preliminary national estimate for Germany as a whole in 1989, based on treatment data, gave a figure of 60 000 to 80 000 individuals who were problem users of opiates, cocaine, stimulants, or hallucinogenic drugs (7). A German expert group estimated the number of heroin users in western and eastern Germany in 1995 at 127 000 to 152 000 (8); for the same year, the number of intravenous drug users in western Germany and Berlin was estimated at a mean of 150 000 (97 000 to 204 000) on the basis of a survey among general practitioners (9).
As part of estimating the number of individuals with problematic drug use in European Union countries, figures of 127 000 to 190 000 opiate users in Germany for the year 2000 were found using various methods. This calculation was based on treatment, police, and mortality data (10). Using these approaches, comparative estimates for 1990, 1995, and 2000 indicated a moderate increase in the number of opiate users (11).
The aim of this study was to estimate the number of individuals addicted to opioids in Germany and its individual federal states for the calendar year 2016.
This estimate is based on substitution treatment registry data, data from inpatient and outpatient addiction care statistics, and counts in 5 low-threshold addiction care facilities. We assume that all data was recorded inasmuch as all individuals addicted to opioids come into some form of contact with the addiction care system. We draw a distinction between individuals who are documented in the addiction care system and those who come into contact with the system but only receive care that is not documented.
Although there are no diagnoses for individuals with no case documentation, it can nevertheless be assumed from care they have received, e.g. needle exchange, that they are addicted to opioids.
Cases are documented when an individual addicted to opioids is prescribed an opioid substitute by his/her treating physician. The coded patient data reported by the doctor to Germany’s Federal Institute for Drugs and Medical Devices (BfArM, Bundesinstitut für Arzneimittel und Medizinprodukte) is added to the substitution treatment registry there in encrypted form (12). Double entries resulting from the same code being used for 2 individuals were ruled out by consulting the treating physicians.
Individuals addicted to opioids are also documented if they receive treatment at inpatient or outpatient addiction care facilities which is recorded in Germany’s Addiction Care Statistical Service, DSHS (Deutsche Suchthilfestatistik) (13). The DSHS data was used to estimate how many individuals were addicted to opioids and did not undergo substitution treatment in addiction care facilities. Cases with “opioid addiction” as primary or secondary diagnosis in various types of addiction care facilities were used. The included facilities are of the following types, as defined in DSHS:
- Low-threshold facilities with case documentation, such as emergency shelters or drug consumption rooms (type 2)
- Outpatient counseling and/or treatment facilities outpatient facilities within institutions, and specialist walk-in clinics (types 3 and 4)
- Semiresidential rehabilitation facilities (type 8)
- Residential rehabilitation facilities (type 9)
- Transition facilities (type 10)
Unlike the substitution treatment registry, the DSHS records treatment episodes rather than individuals and reports only aggregate data, so double entries of individuals cannot be checked. Individuals may be counted twice if they are recorded at both inpatient and outpatient facilities. Correction factors were calculated using Berlin’s Addiction Care Statistical Service (Suchthilfe Berlin) data (15) and used to convert DSHS data on treatment episodes to individual-related data and to estimate the overlap with individuals addicted to opioids and undergoing substitution treatment. Because the DSHS does not cover all addiction care facilities, data was extrapolated to the total number of addiction care facilities (Figure; see eMethods for a detailed description).
Individuals addicted to opioids are not recorded in the DSHS if they attend a low-threshold facility with no case documentation and use its services, e.g. when addiction care is provided together with social work. In order to estimate the size of this group as a proportion of all individuals addicted to opioids, clients at 5 selected facilities in Berlin, Frankfurt, Hamburg, Munich, and Nuremberg were routinely surveyed, for example during needle exchange, at contact points, or at mobile addiction care services. The use of addiction care facilities was surveyed between July and September 2017 as part of regular contact. Addiction professionals recorded clients’ sex and their opioid consumption in the last 12 months and asked which addiction care facilities, by DSHS types, they had attended in the same period. Facilities ruled out double entries using, for example, personal acquaintance, lists of pseudonyms, or statement of characteristics. Clients with insufficient knowledge of German were largely handled by professionals with knowledge of the relevant language (e.g. Farsi, Russian, Turkish). Logistic regression was used to estimate 95% confidence intervals for the percentages of all individuals who used opioids and who used only services with no case documentation, for the sample as a whole and by sex. The facility type was used as control variable.
To estimate the number of individuals addicted to opioids, the estimated percentage of individuals not undergoing substitution treatment and with no case documentation (NST) was added to the number of individuals not undergoing substitution treatment estimated on the basis of the DSHS data (AC). Upper and lower limits were set using the 95% confidence intervals of the estimate of the proportion of individuals with no case documentation (NCD). The total estimate (upper and lower limits) includes the number of individuals undergoing substitution treatment (St + NST). These steps were taken for men and for women.
The number of individuals addicted to opioids for each federal state in Germany was estimated using the number of patients reported as undergoing substitution treatment on the sample day July 1, 2016 in each federal state (12). These figures were used to calculate a percentage for each federal state on the basis of the reported total number.
A total of 123 387 encrypted codes were recorded in the database of the Federal Institute for Drugs and Medical Devices (BfArM) between 1 July, 2016 and 30 June, 2017. After codes entered twice or multiple times had been removed 93 939 different codes remained. A total of 0.99% of the reports were identical by chance and should not have been removed from the total number of codes, so 442 cases (0.99% of 44 887) were added. This led to a figure of 94 381 for the number of patients undergoing substitution treatment in 2016 according to the substitution treatment registry.
Inpatient or outpatient addiction care
The number of individuals addicted to opioids and not undergoing substitution treatment was obtained from the DSHS data in line with the following characteristics:
- Primary diagnoses (ICD-10 codes F10 to F19, F50, F63), including secondary diagnoses F11 (disorders due to use of opioids)
- Type of facility
- Adjustment for possible multiple entries (secondary diagnoses F11, multiple treatments within and between facilities)
The estimated figure was 66 220 individuals (50 953 men and 15 267 women) addicted to opioids and not undergoing substitution treatment.
Low-threshold facilities with no case documentation
A total of 884 individuals addicted to opioids were recorded in routine documentation at the 5 locations. It was estimated that 9.6% (95% confidence interval [CI]: 7.6 to 11.6%) of men and 5.2% (2.1 to 8.4%) of women used only low-threshold facilities or other addiction care with no case documentation.
Estimate for Germany as a whole
The estimated total figure is 166 294 (range: 164 794 to 167 794) individuals addicted to opioids, of whom 123 988 (range: 122 968 to 125 007) are men and 42 307 (range: 41 826 to 42 787) are women (Table 1). As the recorded population of Germany aged between 15 and 64 years in 2016 was 53 963 400 (17), this equates to a rate of 3.05 to 3.11 per thousand inhabitants.
Estimate for federal states
Table 2 shows the estimated numbers of individuals addicted to opioids for individual federal states, based on the registered numbers of individuals undergoing substitution treatment in those states. Estimated rates for federal states range from 0.1 per thousand inhabitants in Brandenburg to 5.5 per thousand in Bremen (see eTable for details).
The estimated number of individuals addicted to opioids in Germany in 2016 is based on the following:
- Documentation of all individuals undergoing substitution treatment reported to the Federal Institute for Drugs and Medical Devices (BfArM)
- A count of clients who are addicted to opioids, reported as receiving inpatient or outpatient addiction care, and not undergoing substitution treatment according to DSHS data
- An estimate of the number of individuals who did not use any of the addiction care facilities stated in the 2 points above
The findings for these 3 points give a total estimate of 166 294 (range: 164 794 to 167 794) individuals addicted to opioids in Germany, of whom 123 988 (range: 122 968 to 125 007) are men and 42 307 (range: 41 826 to 42 787) are women.
There are no current figures for Germany or its federal states except for this estimate and one study in Berlin (18). This estimate is of a similar mean value to earlier estimates from the year 1995—97 000 to 204 000 intravenous drug users in western Germany and Berlin (9)—and from the year 2000—127 000 to 190 000 opiate users in Germany as a whole (10). Although the 1995 estimate was for western Germany and Berlin and concerned intravenous drug users, after Germany’s reunification opioid consumption was almost zero in the new federal states in the 1990s and intravenous use was the most popular route of administration in Western Europe.
Comparisons with earlier estimates of the numbers of individuals addicted to opioids in Berlin are limited by the fact that this evaluation uses only national data, not regional data. Our figures—10 844 to 11 041 individuals addicted to opioids in Berlin—are somewhat lower than the figures for 2010—11 300 to 16 700 individuals addicted to opioids (18). Provided that this is not an overestimate and that the number of people addicted to opioids in Berlin did not change substantially between 2010 and 2016, it cannot be assumed that the number of individuals addicted to opioids who did not undergo substitution treatment and were not registered is proportional to the number of patients undergoing substitution treatment recorded in Germany’s federal states. If it were, the number of individuals addicted to opioids who did not undergo substitution treatment and were not recorded would be higher than estimated here in federal city states and those federal states with large cities and a large drug scene. In contrast, the estimates for other federal states would be slightly overestimated. However, the regional distribution of individuals addicted to opioids who do not undergo substitution treatment and are not registered may also be subject to effects other than those assumed here. Our estimates for federal states are therefore merely approximate.
In our study, the number of individuals addicted to opioids currently undergoing substitution treatment was 56.2 to 57.3% of the total estimate. The findings of the DRUCK study (“DRUCK” = Drogen und Chronische Infektionskrankheiten—“Drugs and chronic infectious diseases”) (19), based on a sample of intravenous drug users addicted to opioids, indicate that 57 to 89% of clients in different cities have ever undergone opioid substitution treatment and 31 to 66% are currently undergoing substitution treatment. Addiction care data for Hamburg (Basisdokumentation BADO) indicates that in 2016 75% of clients diagnosed with opioid addiction were undergoing substitution treatment (20).
Our estimate has a number of limitations. The validity of the data in the substitution treatment registry depends on the completeness and quality of physicians’ reports. There are also the lack of age-specific data in the substitution treatment registry, the conversion of DSHS data on treatment episodes to individual-based data, and the use of Berlin´s Addiction Care Statistical Service (Suchthilfe Berlin) data to calculate correction factors and the associated assumption of representativeness. Other than Berlin´s Addiction Care Statistical Service data, relevant individual-related data is available only for Hamburg, Hesse, and Schleswig-Holstein (20), and this does not allow a representative estimate to be made for Germany either. Finally, it must be pointed out that individuals addicted to opioids who were incarcerated, in facilities for integration into society, or in acute care could not be included in the estimate, even though it can be assumed that there is great overlap with the data sources used. Our estimate should therefore be treated as conservative.
This estimate assumes that almost everyone addicted to opioids is in some kind of contact with the addiction care system. Studies in the open drug scene indicate that a total of 93 to 99% of those surveyed (2010: 99%; 2012: 98%; 2014: 96%; 2016: 93%) have used the addiction care system at least once in the last 3 months, mostly in the area of harm reduction, such as needle exchange or drug consumption rooms (21). However, the existence of a population of opioid users who could potentially be diagnosed with addiction and who cannot be counted among harm reduction service users cannot be ruled out. These might include, for example, individuals who are integrated into society, who have the financial means to procure opioids, and who use opioids with no impact on society or damage to their health.
Epidemiological data indicates that first demand for addiction counseling and/or treatment, the number of first-time users, and the number of drug law violations due to heroin and other opioid use have been decreasing for years. There is also evidence that the range of drugs available has expanded substantially in the last 20 years and that consumption patterns have diversified.
The overall scale of heroin and other opioid use has fallen in recent years, and opioid use seems to be less attractive to young people than stimulant use, for example (22). The increasingly older clients who attend advice and treatment facilities for opioid use and the substantial increase in the mean age of those dying of opioid overdoses in the last 20 years also point in this direction. However, comparison of our estimate with earlier estimates suggests that the number of individuals addicted to opioids in Germany has barely changed in the last 20 years. This can be explained by stagnation of the prevalence of opioid addiction and a decline in its incidence.
Although substitution treatment makes a substantial contribution to ensuring patients’ survival (23), only some 4% of patients per year successfully complete treatment (24–26). At the same time, there is evidence in the literature of a decline in new cases of opioid-related disorders in Europe (27–29). Consequently, prevalence is falling only in the long term, as substitution treatment has been rolled out comprehensively, leading to better survival and the ageing of the population of users as a whole. However, the dramatic increase in opioid-related mortality observed in the USA in the last two decades in the context of liberal prescription of opioid-containing analgesics to patients with chronic, non-cancer-related pain (30) suggests that more attention must be paid to preventing possible iatrogenic opioid addiction disorders using appropriate countermeasures.
The study Estimation of the number of people with opioid addiction in Germany was funded by Germany’s Federal Ministry of Health (file no.: ZMVI1–2517DSM209).
Estimating the number of individuals who have attended low-threshold facilities would have been impossible without the help of addiction care facility staff. We would like to thank the following facilities and their employees for their support: Drob Inn St. Georg Advice and Treatment Center, Hamburg: Christine Tügel and the Drob Innmobile team; Fixpunkt – Verein für suchtbegleitende Hilfen e. V., Berlin: Astrid Leicht and the Kontaktstelle Druckausgleich team, mobile care at Kottbusser Tor and Stuttgarter Platz; JJ Jugendberatung und Jugendhilfe e.V., Frankfurt: Dr. Dieter Kunz, Wolfgang Barth, and the Drug Emergency Unit team; Mudra – Drogenhilfe e.V., Nuremberg: Bertram Wehner, Martin Kießling, Doris Salzmann, and the Contact Café and Streetwork team; Prop e. V. Association for Prevention, Youth Care, and Addiction Treatment, Munich: Regina Radke, Marco Stürmer, Andreas Czerny, Holger Meurer, and the Drug Emergency Unit L 43 (DND) team.
Conflict of interest statement
PD Dr. Verthein has received reimbursement of conference fees and travel costs and lecture fees from Mundipharma GmbH.
The other authors declare that no conflict of interest exists.
Manuscript received on 12 October 2018, revised version accepted on 18 December 2018.
Translated from the original German by Caroline Shimakawa-Devitt, M.A.
Prof. Dr. phil. Ludwig Kraus,
IFT Institute for Therapy Research
For eReferences please refer to:
Department for Public Health Sciences, Stockholm University, Stockholm, Sweden and Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary: Prof. Dr. phil. Ludwig Kraus
Centre of Interdisciplinary Addiction Research (ZIS), University Medical Center Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy: Dr. rer. medic. Bernd Schulte,
PD Dr. phil. Uwe Verthein
German Federal Institute for Drugs and Medical Devices, Federal Opium Agency:
Dr. med. Peter Cremer-Schaeffer
|1.||Degenhardt L, Whiteford HA, Ferrari AJ, et al.: Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564–74 CrossRef|
|2.||Schäfer M: Opioide. In: Tonner PH, Hein L (eds.): Pharmakotherapie in der Anästhesie und Intensivmedizin. Berlin: Springer 2011; 109–30 CrossRef MEDLINE|
|3.||Strathdee SA, Hallett TB, Bobrova N, et al.: HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; 376: 268–84 CrossRef|
|4.||Arendt M, Munk-Jorgensen P, Sher L, et al.: Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend 2011; 114: 134–9 CrossRef|
|5.||Groenemeyer A: Drogen, Drogenkonsum und Drogenabhängigkeit. In: Albrecht G, Groenemeyer A (eds.): Handbuch soziale Probleme. Wiesbaden: Springer 2012; 433–93 CrossRef|
|6.||Babor TF, Caetano R, Casswell S, et al.: Alcohol: no ordinary commodity. Oxford: Oxford University Press 2010 CrossRef|
|7.||Klingemann H, Goos C, Hartnoll R, Jablensky A, Rehm J: European summary on drug abuse. Copenhagen: WHO Regional Office for Europe 1991.|
|8.||Bühringer G, Adelsberger F, Heinemann A, et al.: Schätzverfahren und Schätzungen 1997 zum Umfang der Drogenproblematik in Deutschland. Sucht 1997; 43 (Sonderheft 2): S79–S141.|
|9.||Kirschner W, Kunert M: Umfang und Struktur von i.v. Drogenabhängigen in Deutschland (1995). Anonymes Monitoring in den Praxen niedergelassener Ärzte. München: Profil 1997.|
|10.||Kraus L, Augustin R, Frischer M, et al.: Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. Addiction 2003; 98: 471–85 CrossRef MEDLINE|
|11.||Augustin R, Kraus L: Changes in prevalence of problem opiate use in Germany between 1990 and 2000. Eur Add Res 2004; 10: 61–7 CrossRef MEDLINE|
|12.||Bundesopiumstelle: Bericht zum Substitutionsregister (84.1 / 12.01.2017). www.bfarm.de/SharedDocs/Downloads/DE/Bundesopiumstelle/SubstitReg/Subst_Bericht2017.pdf?__blob=publicationFile&v=2; 2017 (last accessed on 28 January 2019).|
|13.||Thaller R, Specht S, Künzel J, Braun: Suchthilfe in Deutschland 2016. Jahresbericht der deutschen Suchthilfestatistik (DSHS). München: IFT Institut für Therapieforschung 2017. www.suchthilfestatistik.de/fileadmin/user_upload_dshs/Publikationen/Jahresberichte/DSHS_Jahresbericht_2016.pdf (last accessed on 28 January 2019).|
|14.||Strada L, Schmidt CS, Rosenkranz M et al.: Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: a cross-sectional study. Subst Abuse Treat Prev Policy 2019; 14: 2 CrossRef MEDLINE PubMed Central|
|15.||Specht S, Dauber H, Künzel J, Braun B: Suchthilfestatistik 2016. Jahresbericht zur aktuellen Situation der Suchthilfe in Berlin (in Vorbereitung). München: IFT Institut für Therapieforschung 2018.|
|16.||Süss B, Pfeiffer-Gerschel T: Bestimmung der Erreichungsquote der Deutschen Suchthilfestatistik auf Basis des DBDD-Einrichtungsregisters. Sucht 2011; 57: 469–78 CrossRef|
|17.||Statistisches Bundesamt (Destatis): Bevölkerungsstand. Bevölkerung nach Altersgruppen, Familienstand und Religionszugehörigkeit. Wiesbaden: Statistisches Bundesamt (Destatis) 2016; www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Bevoelkerungsstand/Tabellen/AltersgruppenFamilienstandZensus. html (last accessed on 28 January 2019).|
|18.||Kraus L, Steppan M, Piontek D: Schätzung der Prävalenz substanzbezogener Störungen in Berlin: Opioide, Kokain und Stimulanzien. München: IFT Institut für Therapieforschung 2015. www.ift.de/fileadmin/user_upload/Literatur/Berichte/Kraus_Steppan_Piontek_2015_CRC_Berlin.pdf (last accessed on 28 January 2019).|
|19.||Robert Koch-Institut (RKI): Abschlussbericht der Studie „Drogen und chronische Infektionskrankheiten in Deutschland“ (DRUCK-Studie). Berlin: Robert Koch Institut 2016. DOI: 10.17886/rkipubl-2016–007.2.|
|20.||Lindemann C, Neumann-Runde E, Martens MS: Suchthilfe in Hamburg. Statusbericht 2016 der Hamburger Basisdatendokumentation in der ambulanten Suchthilfe und der Eingliederungshilfe. Hamburg: Bado e. V .; 2017.|
|21.||Werse B, Sarvari L, Egger D, Feilberg N: MoSyD – Die offene Drogenszene in Frankfurt am Main 2016. Frankfurt am Main: Centre for Drug Research 2017 MEDLINE PubMed Central|
|22.||Piontek D, Dammer E, Schulte L, Pfeiffer-Gerschel T, Bartsch G, Friedrich M: Bericht 2017 des nationalen REITOX-Knotenpunkts an die EBDD (Datenjahr 2016/2017). Deutschland, Workbook Drogen. München: Deutsche Beobachtungsstelle für Drogen und Drogensucht DBDD 2017.|
|23.||Soyka M, Träder A, Klotsche J, et al.: Mortalität in der langfristigen Substitution: Häufigkeit, Ursachen und Prädiktoren. Suchtmed 2011; 13: 247–52.|
|24.||Wittchen HU, Bühringer G, Rehm J, et al.: Der Verlauf und Ausgang von Substitutionspatienten unter den aktuellen Bedingungen der deutschen Substitutionsversorgung nach 6 Jahren. Suchtmed 2011; 13: 232–46.|
|25.||Verthein U, Götzke C, Strada L, et al.: Completion of opioid substitution treatment – an observational prospective study. Heroin Addict Relat Clin Probl 2017; 19: 49–56.|
|26.||Zippel-Schulz B, Specka M, Cimander K, et al.: Outcomes of patients in long-term opioid maintenance treatment. Subst Use Misuse 2016; 51: 1493–503 CrossRef MEDLINE|
|27.||de Angelis D, Hickman M, Yang S: Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: Back-calculation methods and opiate overdose deaths. Am J Epidemiol 2004; 160: 994–1004 CrossRef MEDLINE|
|28.||Nordt C, Stohler R: Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis. Lancet 2006; 367: 1830–4 CrossRef|
|29.||Sanchez-Niubo A, Fortiana J, Barrio G, et al.: Problematic heroin use incidence trends in Spain. Addiction 2009; 104: 248–55 CrossRef MEDLINE|
|30.||Dhalla, IA, Persaud N, Juurlink, DN: Facing up to the prescription opioid crisis. BMJ 2011; 343: d5142 CrossRef MEDLINE|
Die Substitutionstherapie Opioidabhängiger in Deutschland: Auswirkungen der 3. BtMVVÄndV aus der Sicht substituierender Ärztinnen und ÄrzteDas Gesundheitswesen, 202110.1055/a-1378-9249
Patients’ Perceptions of Opioid Replacement Therapy: a Comparison of Diamorphine and Methadone/LevomethadoneInternational Journal of Mental Health and Addiction, 202110.1007/s11469-020-00313-0
Deutsches Ärzteblatt international, 201910.3238/arztebl.2019.0459a
Behandlung opioidabhängiger Inhaftierter – Einstellungen und Behandlungspraxis des medizinischen Personals in bayerischen JustizvollzugsanstaltenDas Gesundheitswesen, 202110.1055/a-1399-9286
Public Health Forum, 202010.1515/pubhef-2020-0097
Deutsches Ärzteblatt international, 201910.3238/arztebl.2019.0459b
Frontiers in Psychiatry, 202210.3389/fpsyt.2022.868346
Prescription of opioid analgesics for non-cancer pain in Germany: study protocol for a mixed methods analysisJournal of Public Health, 202210.1007/s10389-022-01748-6
Konsumutensilienvergabe in Deutschland: Ergebnisse einer Befragung von Einrichtungen der Drogenhilfe und Suchttherapie zur Ausgabe von Utensilien zum sicheren Drogenkonsum 2018Suchttherapie, 202210.1055/a-1770-9465
Association of Testosterone Levels and Steroid 5-Alpha-Reductase 2 Polymorphisms with Opioid CravingNeuropsychobiology, 202110.1159/000508681
Drogennotfallschulung Opioidabhängiger in Haft und Versorgung mit Take-Home Naloxon bei Haftentlassung: Machbarkeitsstudie aus dem bayerischen ModellprojektDas Gesundheitswesen, 202210.1055/a-1860-1048
Prevalence of Opioid Dependence and Opioid Agonist Treatment in the Berlin Custodial Setting: A Cross-Sectional StudyFrontiers in Psychiatry, 202010.3389/fpsyt.2020.00794
Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others–A Perspective of German Addiction Medicine ExpertsFrontiers in Psychiatry, 202010.3389/fpsyt.2020.592199
Deutsches Ärzteblatt international, 201910.3238/arztebl.2019.0585